What is Onivyde?
Onivyde (nal-IRI) is a chemotherapy drug used to treat patients with advanced pancreatic cancer whose disease has progressed after prior treatment [1]. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [2]. Onivyde is typically administered intravenously in combination with fluorouracil and leucovorin [1].
Why are alternative treatments for pancreatic cancer being sought?
Pancreatic cancer is a challenging disease with a poor prognosis, and many patients' cancers eventually progress despite initial treatment [3]. This necessitates the exploration of alternative therapies that can offer new options for patients who have exhausted standard treatment regimens [3].
How does Onivyde work?
Onivyde works by delivering irinotecan more effectively to tumor cells. The liposomal encapsulation protects irinotecan from rapid degradation in the body and allows for prolonged circulation, leading to sustained drug levels at the tumor site [2]. Once inside the tumor, the irinotecan is released and inhibits topoisomerase I, an enzyme crucial for DNA replication and repair, ultimately leading to cancer cell death [2].
What are other treatment options for advanced pancreatic cancer?
When pancreatic cancer progresses after initial therapy, treatment options may include other chemotherapy regimens, targeted therapies, or immunotherapies, depending on the individual patient's genetic profile and the specific characteristics of their tumor [4]. Clinical trials also represent an important avenue for accessing novel treatments [3]. Some common chemotherapy agents used in pancreatic cancer include gemcitabine, nab-paclitaxel, and FOLFOX (a combination of fluorouracil, leucovorin, oxaliplatin) [4].
When does Onivyde's patent protection expire?
Information regarding the specific patent expiry dates for Onivyde is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks pharmaceutical patent information [5].
What are the risks associated with Onivyde?
The most common side effects of Onivyde include diarrhea, decreased appetite, nausea, vomiting, stomatitis, fatigue, abdominal pain, and hair loss [1]. Serious side effects can include severe diarrhea, neutropenia (low white blood cell count), and febrile neutropenia [1]. Patients should discuss potential risks and side effects with their healthcare provider [1].
Can Onivyde be used in combination with other drugs?
Yes, Onivyde is approved for use in combination with fluorouracil and leucovorin [1]. The specific combination therapy is designed to enhance efficacy and manage potential toxicities [2].
What clinical trials are available for advanced pancreatic cancer?
Numerous clinical trials are ongoing for advanced pancreatic cancer, investigating new drug combinations, novel agents, and different treatment sequences [3]. Patients interested in clinical trials should consult with their oncologist or explore resources that list available studies [3].